EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitNetzwerk-Metaanalyse

Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

Xue-Chen Cao, Jia-Wei Lu, Yi-Fei Feng, Le-Bin Song, Yan Lu

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-024-02971-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Xue-Chen Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, 210029, China. Hauptthemen laut MEDLINE: Boron Compounds, Bridged Bicyclo Compounds, Heterocyclic, Dermatitis, Atopic, Nitriles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the lack of head-to-head studies of novel non-steroidal molecule topical therapies in mild-to-moderate atopic dermatitis (AD), network meta-analyses (NMAs) can provide comparative efficacy and safety data for clinical decision-making. In this NMA, we performed a literature search until 01 March 2023 for eligible studies written in English using databases, including PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov. Only double-blind randomized clinical trials (RCTs) with topical Ruxolitinib, Crisaborole, or Tapinarof versus vehicle for patients with mild-to-moderate AD were included. Baseline and follow-up data were extracted. Efficacy was evaluated using Investigator's Global Assessment (IGA) achieving "clear" or "almost clear," with 2 points or more improvement from baseline at the end of treatment, referred to as "IGA success." For binary outcomes, we analyzed in random-effects Bayesian NMA consistency models to compare the efficacy of these 3 topical therapies by odds ratio (OR) with 95% credibility interval (CrI). Overall, 10 phase 2 or phase 3 RCTs were identified, which included 4010 patients with mild to moderate AD. Compared with the topical vehicle control, all these 3 treatments had higher response rate of "IGA success" at the end of trial (Ruxolitinib 1.5% b.i.d: OR, 11.94; 95%CrI, 6.28-23.15; Crisaborole 2% b.i.d: OR, 2.08; 95%CrI, 1.46-3.52; Tapinarof 1% b.i.d: OR, 2.64; 95%CrI, 0.75-9.70). Notably, Ruxolitinib 1.5% b.i.d. had the highest probability of achieving "IGA success" in ranking analysis (Rank 1, SUCRA = 0.75) and lower risk of AE (Rank 8, SUCRA = 0.22). Besides, there was no difference in treatment-related adverse events between 3 therapies. Heterogeneity was not significant across studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsBridged Bicyclo Compounds, HeterocyclicDermatitis, AtopicNitrilesPyrazolesPyrimidinesHumansBayes TheoremRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

CrisaboroleMild-to-moderate atopic dermatitisNetwork meta-analysisNon-steroidal topical therapiesRuxolitinibTapinarof

Substanzen

Boron CompoundsBridged Bicyclo Compounds, HeterocycliccrisaboroleNitrilesPyrazolesPyrimidinesruxolitinib

Autor:innen und Institutionen

  • Department of Dermatology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, 210029, China.
  • Department of Dermatology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, 210029, China. luyan6289@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cao, X. C., Lu, J. W., Feng, Y. F., Song, L. B., & Lu, Y. (2024). Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-02971-6

Vancouver

Cao XC, Lu JW, Feng YF, Song LB, Lu Y. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-02971-6

BibTeX
@article{Cao2024,
  author = {Cao, Xue-Chen and Lu, Jia-Wei and Feng, Yi-Fei and Song, Le-Bin and Lu, Yan},
  title = {Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-024-02971-6}
}
Kostenlos starten →